Coronary Slow Flow Phenomenon (CSFP). Other forms of angina pectoris
Conditions
Interventions
Intervention 1: Intervention group: Dietary supplement nano-curcumin 80 mg one capsule daily (Exir Nano Sina Co.). Intervention 2: Control group: Placebo supplement one capsule daily (Exir Nano Sina C
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
35 Years to 70 Years
Inclusion criteria
Inclusion criteria: 35 to 70 years old men and women BMI range: 25 - 39.9 Angiographically diagnosed as coronary slow flow phenomenon by Corrected TIMI Frame Count (CTFC) method which is equivalent to 27 or higher for one or more coronary vessels. Normal coronary vessels with coronary stenosis less than 40% Left ventricular ejection fraction higher than 45% Giving informed consent for participation in the study
Exclusion criteria
Exclusion criteria: Premature menopause addiction or alcohol consumption Routine use of NSAIDs or antioxidants one month prior to study Use of aphrodisiac medication within 9 months before study Routine use of corticosteroids or immunosuppressants Use of anticonvulsants Taking antioxidant or omega3 supplements (more than 3 grams per day) at least twice a week within 3 months prior to study Taking vitamin B12, folic acid or vitamin B6 supplements within one month before study Being a professional athlete or execising regularly Uncontrolled hypertension defined as diastolic blood pressure above 90 mmHg, systolic blood pressure above 140 mmHg. Past medical history: hypothyroidism or hyperthyroidism Malignancy Chronic obstructive pulmonary diseases Systemic diseases Connective tissue diseases Renal failure Liver failure Autoimmune diseases Myocardial Infarction Sever heart failure Heart transplant Revascularization procedure or PCI or CABG Left ventricular dysfunction or echocardiographically diagnosed left ventricular hypertrophy Cardiac conduction disturbances Valvular heart disease Atrial fibrillation Aneurysms Cardiomyopathy Congenital heart disease Coronary artery disease Hematologic disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum Homocysteine levels. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Enzymatic Kit.;Serum Adropin levels. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA kit.;Serum Endocan levels. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA kit.;Different aspects of angina pectoris. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Seattle Angina Questionnore.;Serum visfatin level. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA kit.;Serum hs-CRP level. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA kit.;Serum uric acid level. Timepoint: Before and after 12 weeks of intervention. Method of measurement: enzymatic kit.;Quality of life. Timepoint: Before and after 12 weeks of intervention. Method of measurement: SF-36 items questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Body composition analysis. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Bio-electrical impedance analysis.;Serum lipid profile. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Enzymatic Kit.;Serum alkaline phosphatase levels. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Enzymatic Kit.;Serum insulin level. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA kit.;Serum urea level. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Enzymatic Kit.;Serum creatinine level. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Enzymatic Kit.;Fasting Blood Sugar. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Enzymatic Kit.;Hemoglobin A1C. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Turbidimetry.;Complete Blood Count(CBC). Timepoint: Before and after 12 weeks of intervention. Method of measurement: Sysmex. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahsa Rezaei
Tehran University of Medical Sciences
Outcome results
None listed